

# Sareum Holdings PLC

08:40 23 Apr 2019

## Sareum Holdings jumps as it says new data on cancer drug to be released at top conference

Sareum Holdings PLC (LON:SAR) shares jumped on Tuesday as the firm said data from a potential cancer drug it developed will be showcased at the world's leading oncology conference.

Updated results from a Phase I/IIa studies carried out on SRA737 by licensing partner Sierra Oncology will be delivered in the form of two abstracts at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1.

The Sareum-discovered drug candidate is what's known as a checkpoint kinase 1 (CHK1) inhibitor.

CHK1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally by chemotherapy or radiotherapy.

The new treatment is being trialled in women with ovarian cancer, both as a single therapy and in harness with chemotherapy called gemcitabine.

The ASCO abstracts cover new data on the two approaches to treating the killer disease.

In afternoon trading, Sareum shares were 7.1% higher at 0.75p.

-- Adds share price --

**Price:** 0.345p

**Market Cap:** £1117980000M

### 1 Year Share Price Graph



August 2018 February 2019 August 2019

### Share Information

**Code:** SAR

**Listing:** AIM

**52 week High Low**  
0.87p 0.26p

**Sector:** Pharma & Biotech

**Website:** [www.sareum.com](http://www.sareum.com)

### Company Synopsis:

*Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors

may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.